778
Views
0
CrossRef citations to date
0
Altmetric
Company Profile

Tabula Rasa Healthcare Company Profile: Involvement in Pharmacogenomic and Personalized Medicine Research

, , ORCID Icon, ORCID Icon, ORCID Icon, & ORCID Icon show all
Pages 731-735 | Received 07 Jun 2021, Accepted 28 Jun 2021, Published online: 21 Jul 2021

References

  • Toleos A . Press release: millions of older Americans harmed by too many medications. https://lowninstitute.org/press-release-millions-of-older-americans-harmed-by-too-many-medications/
  • Garber J . Lown Institute. Eliminating medication overload: a national action plan. (2020). https://lowninstitute.org/wp-content/uploads/2020/01/lown-eliminating-medication-overload-web.pdf
  • Lown Institute . GarberJ , BrownleeS.Medication overload: America’s other drug problem. (2019). https://lowninstitute.org/reports/medication-overload-americas-other-drug-problem/
  • Lima JJ , ThomasCD , BarbarinoJet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin. Pharmacol. Ther.109(6), 1417–1423 (2021).
  • Al Rihani SB , SmithMK , BikmetovRet al. Risk of adverse drug events following the virtual addition of COVID-19 repurposed drugs to drug regimens of frail older adults with polypharmacy. J. Clin. Med.9(8), 2591 (2020).
  • Smith MK , BikmetovR , AlRihani SBet al. Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients’drug regimens: a drug safety simulation study. Clin.Transl. Sci. doi:10.1111/cts.13025 (2021) ( Epub ahead of print).
  • Michaud V , DeodharM , ArwoodM , AlRihani SB , DowP , TurgeonJ. ACE2 as a therapeutic target for COVID-19:its role in infectious processes and regulation by modulators of the RAAS system. J. Clin. Med.9(7), 2096 (2020).
  • Bingham JM , ArlingtonL , MadhatF , MichaudV , TurgeonJ. Adherence takes hit during pandemic. Pharmacy Times1(1), (2020).
  • Bingham JM , TranchinaK , TurgeonJ. Telepharmacy offers opportunity amid pandemic. Pharmacy Times89(1), (2021).
  • Bain KT , KnowltonCH. Role of opioid-involved drug interactions in chronic pain management. J. Am. Osteopath. Assoc.119(12), 839–847 (2019).
  • Ballinghoff TBK , MatosA , BardoliaC , TurgeonJ , AminNS. Opioid response in an individual with altered cytochrome P450 2D6 activity: implications of a pharmacogenomics case. Clin. Case Rep. J.1(6), 1–4 (2020).
  • Cicali B , VerziccoJ , KnowltonCH , TurgeonJ , MichaudV. Increased risk medication related problems due to concomitant administration of CYP2D6-dependent opioids and CYP2D6 interacting drugs. Presented at: 119th Annual Meeting of American Society for Pharmacology and Therapeutics.FL, USA (2018).
  • Deodhar M , DowP , AlRihani SB , TurgeonJ , MichaudV. An illustrative case of phenoconversion due to multi-drug interactions. Clin. Case Rep. J.1(3), 1–6 (2020).
  • Matos A , BankesDL , BainKT , BallinghoffT , TurgeonJ. Opioids, polypharmacy, and drug interactions: a technological paradigm shift is needed to ameliorate the ongoing opioid epidemic. Pharmacy (Basel)8(3), 154 (2020).
  • Michaud V , CicaliB , VerziccoJ , KnowltonCH , TurgeonJ. Yearly medical expenditure in patients treated with CYP2D6-dependent opioids and impact of concomitant treatment with CYP2D6 substrate or inhibitor drugs. Presented at: 119th Annual Meeting of American Society for Pharmacology and Therapeutics.FL, USA (2018).
  • Gravel S , ChiassonJ-L , TurgeonJ , GrangeonA , MichaudV. Modulation of CYP450 activities in patients with Type 2 diabetes. Clin. Pharmacol. Ther.106(6), 1280–1289 (2019).
  • Bain KT , McGainD , CicaliEJ , KnowltonCH , MichaudV , TurgeonJ. Precision medication: an illustrative case series guiding the clinical application of multi-drug interactions and pharmacogenomics. Clin. Case Rep.8(2), 305–312 (2019).
  • Leal S . Environmental scan of pharmacogenomics in health care HIT infrastructure: pharmacy health information technology collaborative. (2020). http://www.pharmacyhit.org/pdfs/workshop-documents/FINAL_PHITPGx.pdf
  • Michaud V , TranM , PronovostBet al. Impact of GSTA1 polymorphisms on busulfan oral clearance in adult patients undergoing hematopoietic stem cell transplantation. Pharmaceutics11(9), 440 (2019).
  • Michaud V , TurgeonJ. Precision medicine: applied concepts of pharmacogenomics in patients with various diseases and polypharmacy. Pharmaceutics13(2), 197 (2021).
  • Shaw K , AmstutzU , KimRBet al. Clinical practice recommendations on genetic testing of CYP2C9 and VKORC1 variants in warfarin therapy. Ther. Drug Monit.37(4), 428–436 (2015).
  • Bain KT , KnowltonCH , TurgeonJ. Medication risk mitigation: coordinating and collaborating with health care systems, universities, and researchers to facilitate the design and execution of practice-based research. Clin. Geriatr. Med.33(2), 257–281 (2017).
  • Schwartz EJ , TurgeonJ , PatelJet al. Implementation of a standardized medication therapy management plus approach within primary care. J. Am. Board Fam. Med.30(6), 701–714 (2017).
  • Bain KT , SchwartzEJ , KnowltonOV , KnowltonCH , TurgeonJ. Implementation of a pharmacist-led pharmacogenomics service for the Program of All-Inclusive Care for the Elderly (PHARM-GENOME-PACE). J. Am. Pharm. Assoc.58(3), 281–9.e1 (2018).
  • Bain KT , KnowltonCH , MatosA. Cost avoidance related to a pharmacist-led pharmacogenomics service for the Program of All-Inclusive Care for the Elderly. Pharmacogenomics21(10), 651–661 (2020).
  • Perera PN , GuyMC , SweaneyAM , BoesenKP. Evaluation of prescriber responses to pharmacist recommendations communicated by fax in a medication therapy management program (MTMP). J. Manag. Care Pharm.17(5), 345–354 (2011).
  • Rodrigues CR , HarringtonAR , MurdockNet al. Effect of pharmacy-supported transition-of-care interventions on 30-day readmissions: a systematic review and meta-analysis. Ann. Pharmacother.51(10), 866–889 (2017).
  • Turgeon J , MichaudV. Clinical decision support systems: great promises for better management of patients’ drug therapy. Expert Opin. Drug Metab. Toxicol.12(9), 993–995 (2016).
  • Bankes DL , JinH , FinnelSet al. Association of a novel medication risk score with adverse drug events and other pertinent outcomes among participants of the Programs of All-Inclusive Care for the Elderly. Pharmacy (Basel)8(2), 87 (2020).
  • Ratigan AR , MichaudV , TurgeonJet al. Longitudinal association of a medication risk score with mortality among ambulatory patients acquired through electronic health record data. J.Patient Saf.17(4), 249–255 (2021).
  • Bain KT , MatosA , KnowltonCH , McGainD. Genetic variants and interactions from a pharmacist-led pharmacogenomics service for PACE. Pharmacogenomics20(10), 709–718 (2019).
  • Doan J , Zakrzewski-JakubiakH , RoyJ , TurgeonJ , TannenbaumC. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann. Pharmacother.47(3), 324–332 (2013).
  • Deodhar M , AlRihani SB , ArwoodMJet al. Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics12(9), 846 (2020).
  • Zhou Y , Ingelman-SundbergM , LauschkeVM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin. Pharmacol. Ther.102(4), 688–700 (2017).